Elevated carbohydrate antigen 19-9 levels in a patient with choledocholithiasis

Turkish Journal of Gastroenterology

Volumn 13, Issue 4, 2002, Pages 213-215

  Gürbüz, Ahmet K ^a   Melih Ozel A ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

CA19 9; Choledocholithiasis

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; CASE REPORT; CHOLECYSTECTOMY; CLINICAL FEATURE; COMMON BILE DUCT STONE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; PANCREAS CANCER; PHYSICAL EXAMINATION; T TUBE; TREATMENT OUTCOME;

EID: 0036953954     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Koprowski H, Herlyn M, Steplewski Z, et al. Specific antigen in serum of patients with colon carcinoma. Science 1981; 212: 53-5.
2. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-71.
3. Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreatico-biliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999; 94: 1941-6.
4. Steinberg W. The clinical utility of CA 19-9 tumor associated antigen. Am J Gastroenterol 1990; 85; 350-5.
5. Heptner G, Domschke S, Schneider MU, et al: Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases. Dtsch Med Wochenschr 1985; 110: 624-8.
6. Akdogan M, Sasmaz N, Kayhan B, et al. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 2001; 87: 337-9.
7. Peterli R, Meyer-Wyss B, Herzog U, et al:CA19-9 has no value as a tumor marker in obstructive jaundice. Schweiz Med Wochenschr 1999; 129: 77-9.
8. Tolliver BA, O'Brien BL. Elevated tumor-associated antigen CA 19-9 in a patient with an enlarged pancreas: does it always imply malignancy? South Med J 1997; 90: 89-90.
9. Suzuki K, Muraishi, Tokue A. The correlation of serum carbohydrate antigen19-9 with benign hydronephrosis. J Urology 2002; 167:16-20.
10. Murohisa T, Sugaya H, Tetsuka I, et al. A case of common bile duct stone with cholangitis presenting an extraordinarily high serum CA19-9 value. Intern Med 1992; 31: 516-20.
11. Gupta MK, Arciaga R, Bocci L, et al. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen. Cancer 1985; 56: 277-83.
12. Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999; 94: 1941-6.
13. Ohshio G, Manabe T, Watanabe Y, et al. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Am J Gastroenterol 1990; 85: 1370-6.
14. Buccheri GF, Ferrigno D, Sartoris AM, et al. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer 1987; 60: 42-50.
15. Heptner G, Domschke S, Schneider MU, et al. Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases. Dtsch Med Wochenschr 1985; 110: 624-8.